QIAGEN Website    Quick Order    Online Seminar    Contact    My Account
Home  >  Products  >  qBiomarker Somatic Mutation Home  >  PCR Array  >  Oncogene and Tumor Suppressor Panel 384HT Mutation PCR Array

Oncogene and Tumor Suppressor Panel 384HT Mutation PCR Array

Human
 
qBiomarker Somatic Mutation PCR Array: Human Oncogene and Tumor Suppressor Panel 384HT
The Human Oncogene and Tumor Suppressor Panel qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, comprehensive, and accurate profiling of the somatic mutation status of 36 key oncogenes and tumor suppresors of the human cancer genome. Genes covered on this panel are among the most frequently mutated in human cancers and therefore warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human Oncogene and Tumor Suppressor Panel qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for the study of mutations in all major oncogenes and tumor suppressors and has the potential for discovery and verification of drug target biomarkers for a variety of human cancers. This array includes 346 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human oncogenes and tumor suppressors. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments. Researchers with interest in in-depth mutation analysis for a specific pathway or disease are encouraged to explore relevant pathway- or disease-specific somatic mutation PCR arrays. Additional mutation assays (not included in this array) for the majority of the genes are also available.

 

Assay Functional Annotations How It Works References Resources
 
Modify this Array   

(Number of mutation assays for each gene follows the gene symbol)

ABL1

7

AKT1

1

ALK

2

APC

9

BRAF

12

CDKN2A

16

CSF1R

1

CTNNB1

33

EGFR

27

ERBB2

2

EZH2

3

FBXW7

4

FGFR3

8

FLT3

3

GNAQ

2

GNAS

6

HRAS

13

IDH1

5

IDH2

4

JAK2

6

KIT

32

KRAS

21

MET

3

NF2

7

NOTCH1

8

NPM1

6

NRAS

17

PDGFRA

6

PIK3CA

26

PTEN

7

RB1

2

RET

3

SRC

1

STK11

5

TP53

32

VHL

6

 

Assay Functional Annotations How It Works References Resources
 

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS®

Back to Top

 

Assay Functional Annotations How It Works References Resources
 
  1. The PKB/AKT pathway in cancer.Carnero A. Curr Pharm Des. 2010 Jan; 16(1):34-44
  2. BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT, McArthur G. Cancer. 2010 Jul 13. [Epub ahead of print]
  3. Clinical relevance of KRAS in human cancers. Jancík S, Drábek J, Radzioch D, Hajdúch M. J Biomed Biotechnol. 2010; 2010:150960.
  4. Oncogenic Ras in tumour progression and metastasis. Giehl K. Biol Chem. 2005 Mar; 386(3):193-205
  5. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. Proc Natl Acad Sci U S A. 2009 Dec 1; 106(48):20411-6
  6. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. Cell Cycle. 2009 May 1; 8(9):1352-8
  7. Oncogenic mutations as predictive factors in colorectal cancer. Ličvre A, Blons H, Laurent-Puig P. Oncogene. 2010 May 27; 29(21):3033-43
  8.  PI(3)King Apart PTEN's Role in Cancer. Zhang S, Yu D. Clin Cancer Res. 2010 Jul 8. [Epub ahead of print]
Back to Top
 

Assay Functional Annotations How It Works References Resources
 

User Manual qBiomarker Somatic Mutation PCR Array System (PDF)
Data Analysis qBiomarker Somatic Mutation PCR Array Data Analysis Software
Application Data Detection Limits, Cancer Pathways
FAQ Frequently Asked Questions about Somatic Mutation Assays and Arrays
Webinar qBiomarker Somatic Mutation Analysis: Real-World Application Data
Slide Presentation> Presentation about qBiomarker Somatic Mutation Assays and Arrays (PDF)
Scientific Poster A Novel Tool for Pathway-Focused Cancer Mutation Profiling (PDF)
Presented at American Association for Cancer Research 2011
White Paper Rapid and accurate cancer somatic mutation profiling with the qBiomarker Somatic Mutation PCR Array (PDF)
Product Profile For screening biology-focused panels of gene mutations (PDF)

Back to Top